insights_auto
Why is DUL down 2,24%?
Dive Deeperchevron_right
DUL:ETR
Alnylam Pharmaceuticals, Inc.
200,90 €
arrow_downward
-2,24%(-4,60) 1D
13 қаз., 17:35:52 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DUL...
Open
202,60 €
High
202,60 €
Low
200,90 €
Mkt. cap
29,95 млрд
Avg. vol.
39,00
Volume
0,00
52-wk high
417,40 €
52-wk low
177,10 €
No. of employees
2 мың
Open
202,60 €
High
202,60 €
Low
200,90 €
Mkt. cap
29,95 млрд
Avg. vol.
39,00
Volume
0,00
52-wk high
417,40 €
52-wk low
177,10 €
No. of employees
2 мың
News stories
From web sources and news partners
Benzinga
·
1 сағат бұрын
If You Invested $1000 In Alnylam Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today
Investing.com Canada
·
14 сағат бұрын
Form 4 Alnylam Pharmaceuticals Inc For: 13 October By Investing.com
Investing.com
·
2 күн бұрын
Alnylam EVP Bryan Supran sells $398,855 in shares
Simply Wall Street
·
2 күн бұрын
How Securities Fraud Scrutiny Will Impact Alnylam Stock Investors
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.